| Excerpt | Reference |
|---|
| "Gastrointestinal stromal tumors are the most frequent mesenchymal tumors in the gastrointestinal tract." | ( Aparicio, J; Fernández, A, 2004) |
| "Gastrointestinal stromal tumors are rare tumors of the gastrointestinal tract." | ( Conroy, WP; Finkelstein, SD; Lo, SS; Papachristou, GI; Ramanathan, RK; Schraut, WH, 2005) |
| "Gastrointestinal stromal tumors are one of the first solid tumor types in which specific factors responsible for malignant behavior have been elucidated and for which drugs specifically targeting these factors form the mainstay of treatment in advanced-stage disease." | ( Seynaeve, C; Sleijfer, S; Verweij, J; Wiemer, E, 2006) |
| "Gastrointestinal stromal tumors are neoplastic lesions that arise from the interstitial cells of Cajal and are associated with somatic mutations in the tyrosine kinase receptor, KIT." | ( Bickenbach, K; Kindler, HL; Noffsinger, A; Posner, MC; Roggin, KK; Veerapong, J; Wilcox, R, 2007) |
| "Gastrointestinal stromal tumors are rare causes of gastrointestinal bleeding." | ( Baltaci, S; Kankaya, D; Reşorlu, B; Reşorlu, M; Savaş, B, 2007) |
| "Gastrointestinal stromal tumors are relatively rare soft-tissue neoplasms arising from the gastrointestinal tract." | ( Arce-Lara, C; Benson, DM; Clinton, SK; Jimenez, RE; Monk, JP; Patel, VR; Shah, MH, 2007) |
| "Gastrointestinal stromal tumor is the most common mesenchymal tumor in the gastrointestinal tract." | ( Chan, YJ; Chang, WH; Chen, MJ; Hung, CY; Liu, TP; Shih, SC; Wang, TE, 2008) |
| "GIST (gastrointestinal stromal tumor) is a rare soft tissue malignancy arising in the gut." | ( D'Adamo, D, 2009) |
| "Gastrointestinal stromal tumors are the most common mesenchymal neoplasm of the gastrointestinal tract." | ( Bae, SH; Baeg, MK; Jin, JY; Kim, J; Lee, KH; Park, IS, 2011) |
| "Gastrointestinal stromal tumor is the most common mesenchymal tumor of the gastrointestinal tract." | ( Enomoto, M; Higuchi, T; Iida, S; Ishiguro, M; Ishikawa, T; Kato, S; Kikuchi, A; Kobayashi, H; Ono, H; Sugihara, K; Uetake, H; Yamauchi, S; Yasuno, M; Yoshimura, T, 2010) |
| "Rectal gastrointestinal stromal tumors are rare." | ( Agaimy, A; Daniels, M; Evert, M; Lasota, J; Lüders, P; Miettinen, M; Müller, G; Pelz, AF; Röpke, A; Schneider-Stock, R; Schulz, HU; Wieacker, P, 2011) |
| "Gastrointestinal stromal tumors are CD117 (C-Kit) positive mesenchymal neoplasms considered to originate from the interstitial cells of Cajal." | ( Agrawal, V; Pandey, R; Vij, M, 2011) |
| "Gastrointestinal stromal tumors are the commonest stromal tumors of the digestive tract." | ( Cuerva-González, MJ; de la Calle-Fernández, M; Lacoponi, S; Pozo-Krielinger, J, 2010) |
| "Gastrointestinal stromal tumors are very rare mesenchymal tumors of the gastrointestinal tract with variable clinical presentations depending on the tumor size and anatomic site." | ( Agayeva, A; Andican, A; Gökçal, F; Gülşen, F; Özben, V; Özden, F, 2012) |
| "Gastrointestinal stromal tumors are very rare." | ( Dimitrova, V; Taneva, I, 2011) |
| "Gastrointestinal stromal tumors are uncommon intra-abdominal tumors." | ( Cerullo, C; Fonte, C; Iori, A; Lunghi, A; Molinara, E; Neri, B; Pellegrini, E; Rediti, M, 2014) |
| "Gastrointestinal stromal tumors are rare malignancies characterized by c-kit and PDGFR-α mutations targeted by imatinib." | ( Amadori, D; Bongiovanni, A; Calpona, S; Cavaliere, D; De Vita, A; Foca, F; Gunelli, E; Ibrahim, T; La Manna, F; Liverani, C; Mercatali, L; Oboldi, D; Pieri, F; Ricci, M; Riva, N, 2014) |
| "GIST (gastrointestinal stromal tumor) are the most common mesenchymal tumors in gastrointestinal tract and are thought to derive from the cells of Cajal or their precursors that have a constitutional mutation in KIT and PDGFRA genes." | ( Boglione, A; Comandone, A, 2015) |
| "Unresectable gastrointestinal stromal tumors are considered a systemic disease; therefore, imatinib therapy is currently the primary treatment option in these cases." | ( Fujiwara, Y; Fukuda, S; Inoue, M; Kitani, K; Ohta, Y; Tsujie, M; Wakasa, T; Yukawa, M, 2017) |
| "Gastrointestinal stromal tumors are the most common mesenquimal neoplasms of the gastrointestinal tract." | ( Cabezas–Palacios, MN; Fernández–Ruiz, M; Rodríguez–Zarco, E; Tato–Varela, S, 2016) |
| "Gastrointestinal stromal tumors are encountered more frequent as a result of increased imaging examinations." | ( Basaran, A; Kurt, F; Ozlu, O; Yazar, BC, 2021) |
| "Gastrointestinal stromal tumors are more frequently encountered by the surgeons with the help of imaging techniques." | ( Basaran, A; Kurt, F; Ozlu, O; Yazar, BC, 2021) |
| "Rectal gastrointestinal stromal tumors are rare and optimal treatment is yet to be defined." | ( Amaadour, L; Arifi, S; Benbrahim, Z; Berrad, S; Mellas, N; Oualla, K, 2022) |
| "Primary hepatic gastrointestinal stromal tumor is an extremely rare type of liver tumor with an unknown origin and poor prognosis and usually lacking specific symptoms." | ( Huang, Z; Jiang, Y; Lou, C; Lu, Q, 2023) |
| Excerpt | Reference |
|---|
| "We discuss two cases of metastatic gastrointestinal stromal tumors with a good response to imatinib, and also review the pathophysiology and treatment-related outcome of this type of tumors." | ( Aparicio, J; Fernández, A, 2004) |
| "Recent breakthroughs regarding gastrointestinal stromal tumors (GIST) and their pathogenesis have redefined diagnostic criteria and have led to the development of molecularly targeted drug therapy." | ( Bümming, P; Dortok, A; Gustavsson, B; Kindblom, LG; Meis-Kindblom, JM; Nilsson, B; Odén, A; Sablinska, K, 2005) |
| "A specific treatment for gastrointestinal stromal tumors (GIST) has been found through improved understanding of the molecular mechanism of carcinogenesis." | ( de Mestier, P; des Guetz, G, 2005) |
| "We report a gastrointestinal stromal tumor (GIST) patient with male gynecomastia and testicular hydrocele after treatment with imatinib mesylate." | ( Chang, HM; Kang, HJ; Kang, YK; Kim, H; Kim, SE; Kim, TW; Lee, JS; Park, S; Ryu, MH; Sohn, HJ, 2005) |
| "There is now considerable interest in gastrointestinal stromal tumor (GIST) because it can be treated effectively with a targeted molecular agent." | ( DeMatteo, RP; van der Zwan, SM, 2005) |
| "Although most patients with gastrointestinal stromal tumor (GIST) treated with imatinib mesylate achieve remission or disease stabilization, a significant proportion show progressive disease (PD) with or without initial favorable responses." | ( Chang, HM; Kang, HJ; Kang, YK; Kim, TW; Lee, JL; Lee, JS; Ryu, MH; Sohn, HJ, 2006) |
| "The natural history of gastrointestinal stromal tumor (GIST) has been revolutionized by imatinib mesylate (imatinib) therapy." | ( Benjamin, RS; Choi, H; Medeiros, LJ; Oyarzo, M; Raymond, AK; Steinert, DM; Thall, PF; Trent, JC; Wang, X; Zhang, W, 2006) |
| "Treatment of gastrointestinal stromal tumor (GIST) is a paradigm for targeted therapy." | ( von Mehren, M, 2006) |
| "The majority of gastrointestinal stromal tumors harbor mutations in the receptor tyrosine kinases KIT or platelet-derived growth factor receptor A (PDGFRA), and respond to treatment with the tyrosine kinase inhibitor imatinib." | ( Cools, J; Debiec-Rychter, M; Folens, C; Marynen, P; Mentens, N; Prenen, H; Schöffski, P; Sciot, R; Van Oosterom, A, 2006) |
| "The therapy for gastrointestinal stromal tumor (GIST) has been revolutionized by imatinib mesylate (IM)." | ( Benjamin, RS; Chirieac, LR; Choi, H; Patel, SR; Raymond, AK; Steinert, DM; Trent, JC; Yang, Y; Zhang, J, 2006) |
| "The literature on gastrointestinal stromal tumors (GISTs) has rapidly expanded and has demonstrated how scientific advancements in diagnosis can revolutionize the understanding of disease, while paving the way for effective treatment." | ( Driman, DK; Parfitt, JR; Riddell, RH; Streutker, CJ, 2006) |
| "Surgical resection of gastrointestinal stromal tumors (GISTs) has been the most effective therapy for these rare tumors." | ( Andtbacka, RH; Benjamin, RS; Burgess, MA; Chen, LL; Cormier, JN; Feig, BW; Hunt, KK; Ng, CS; Patel, SR; Pisters, PW; Pollock, RE; Raymond, K; Scaife, CL; Trent, J, 2007) |
| "Optimal management of gastrointestinal stromal tumor-induced hypoglycemia requires a multidisciplinary approach, and surgical debulking is the treatment of choice to obtain immediate symptom relief." | ( Buckley, L; Escobar, GA; Gonzalez, R; Heiple, DC; McCarter, MD; Nydam, TL; Robinson, WA; Weiss, GJ, 2007) |
| "A 41-year old female with metastatic gastrointestinal stromal tumor was referred to 18F-FDG-positron emission tomography and computed tomography (PET/CT) scan before and after one-month treatment with imatinib (Glivec, Gleevec, Novartis, Basel, Switzerland), a tyrosine kinase inhibitor (400 mg/d)." | ( Camci, C; Kalender, ME; Sevinc, A; Zincirkeser, S, 2007) |
| "We report here a case of metastatic gastrointestinal stromal tumors with a dramatic long duration of response after treatment with concurrent radiotherapy and imatinib mesylate." | ( Akmansu, M; Atik, ET; Boruban, C; Ozbek, S; Sencan, O, 2007) |
| "The outcome of patients with gastrointestinal stromal tumors has been dramatically improved by therapy with imatinib mesilate (imatinib mesylate), a KIT and platelet-derived growth factor (PDGFR) tyrosine kinase inhibitor." | ( Papadopoulos, KP; Sankhala, KK, 2007) |
| "Therapy for gastrointestinal stromal tumors (GIST) has changed significantly with the use of imatinib mesylate (IM)." | ( Blanke, CD; Demetri, GD; Eisenberg, BL; Harris, J; Heinrich, MC; Hoffman, JP; Kane, JM; Okuno, S; von Mehren, M; Watson, JC, 2009) |
| "Diagnostic and treatment strategies for gastrointestinal stromal tumors (GISTs) have evolved greatly since the introduction of molecularly targeted therapies." | ( Hirota, S; Kubota, T; Minami, M; Nishida, T; Otani, Y; Shimada, Y; Sugino, Y; Takahashi, F; Yamamura, Y; Yanagisawa, A, 2008) |
| "The management of gastrointestinal stromal tumors (GISTs) has been revolutionized in recent years by two major developments: the introduction of imatinib mesylate as a targeted therapeutic agent and the dramatic change in the tumor metabolic activity following successful therapy making in fluorodeoxyglucose (FDG)-PET as the modality of choice for monitoring therapeutic response." | ( Asopa, R; Basu, S; Mohandas, KM; Peshwe, H; Vyawahare, M, 2008) |
| "Clinical outcomes of gastrointestinal stromal tumor (GIST)-bearing patients treated with imatinib mesylate (IM) are variable." | ( Blay, JY; Borg, C; Chaput, N; Delahaye, NF; Emile, JF; Flament, C; Ghiringhelli, F; Le Cesne, A; Ménard, C; Michiels, S; Nonn, C; Robert, C; Taïeb, J; Zitvogel, L, 2009) |
| "Due to the rarity of esophageal gastrointestinal stromal tumors (GISTs), their clinical course and treatment are poorly understood." | ( Kim, DK; Kim, YH; Lee, HJ; Park, SI, 2009) |
| "Recurrence of a gastrointestinal stromal tumor (GIST) may require multimodal therapy and the role of repeated surgery in this concept is unclear." | ( Bachmann, K; Bogoevski, D; Izbicki, J; Kaifi, J; Kohrs, D; Reichelt, U; Schurr, P; Vashist, Y; Yekebas, E, 2009) |
| "Surgical indication for metastatic gastrointestinal stromal tumor (GIST) treated with imatinib is not yet established." | ( Casali, PG; Fiore, M; Gronchi, A; Hohenberger, P; Jakob, J; Mussi, C; Reichardt, P; Ronellenfitsch, U; Tamborini, E, 2010) |
| "Fourteen patients with gastrointestinal stromal tumor who had been treated with imatinib for 7 to 61 months underwent 26 sessions of embolotherapy." | ( Ahrar, K; Ensor, J; Gupta, S; Hicks, ME; Kobayashi, K; Madoff, DC; Murthy, R; Szklaruk, J; Trent, JC; Wallace, MJ, 2009) |
| "The finding of mutations of KIT in gastrointestinal stromal tumors (GISTs) and subsequent development of kinase-directed therapy in metastatic GIST serve as a touchstone for the translation of laboratory research into clinical therapeutics." | ( Benjamin, RS; Debiec-Rychter, M; Demetri, GD; Joensuu, H; Le Cesne, A; Poveda, A; Schöffski, P; Sleijfer, S, 2009) |
| "Diagnosis and treatment of gastrointestinal stromal tumors (GIST) requires an interdisciplinary treatment approach." | ( Bareck, E; Brodowicz, T; Eisterer, W; Häfner, M; Kühr, T; Längle, F; Ploner, F; Schima, W; Wrba, F; Zacherl, J, 2009) |
| "Adjuvant treatment of gastrointestinal stromal tumor (GIST) patients with Imatinib (400 mg/d) is associated with a statistically significant improvement of relapse-free survival." | ( Brodowicz, T; Kühr, T, 2009) |
| "A patient with a gastrointestinal stromal tumor (GIST) who developed a type I HSR to sunitinib and who was successfully treated by drug desensitization is reported." | ( Atrash, F; Bar-Sela, G; Hadad, S; Haim, N; Kedem, E; Pollack, S; Shahar, E, 2010) |
| "We report a case of a large gastric gastrointestinal stromal tumor (GIST), which we were able to curatively resect after treatment with a daily dosage of 400 mg imatinib for 3 months." | ( Kadokawa, Y; Kawabe, A; Nakajima, S; Sonoda, K; Yamamoto, T, 2009) |
| "Most gastrointestinal stromal tumor (GIST) patients respond to KIT inhibition therapy of imatinib, but eventually become resistant with a median time to progression of 2 years." | ( Du, CY; Fu, H; Huang, K; Shi, YQ; Wang, CM; Ye, YW; Zhou, XY; Zhou, Y, 2010) |
| "Thus, a gastrointestinal stromal tumor (GIST) was diagnosed and imatinib treatment was begun." | ( Akiyoshi, T; Fujimoto, Y; Hatake, K; Katori, M; Kuroyanagi, H; Muto, T; Oya, M; Takahashi, S; Ueno, M; Yamaguchi, T; Yamamoto, N, 2010) |
| "Secondary resistance of gastrointestinal stromal tumors (GISTs) to tyrosine kinase inhibitors occurs after several years' administration." | ( Bamba, T; Hasegawa, T; Hironaka, M; Hirota, S; Hishima, T; Kanda, T; Keira, Y; Niki, T; Sakamoto, K; Sakuma, Y; Sakurai, S; Takano, Y, 2010) |
| "We report a case of gastrointestinal stromal tumor (GIST) with liver metastases which was undetectable by B-mode ultrasonography, effectively treated by radiofrequency ablation using contrast-enhanced ultrasonography US." | ( Ebihara, T; Ishida, Y; Kondo, S; Matsuda, R; Minami, T; Sato, S; Tanaka, T; Togo, G; Watanabe, Y; Yamada, A; Yamazaki, K; Yotsuya, S, 2010) |
| "Although gastrointestinal stromal tumors (GISTs) harboring activating KIT or platelet-derived growth factor receptor A (PDGFRA) mutations respond to treatment with targeted KIT/PDGFRA inhibitors such as imatinib mesylate, these treatments are rarely curative." | ( Debiec-Rychter, M; Debnath, J; Floris, G; Gupta, A; Lazar, AJ; McAuliffe, JC; McMahon, J; Reynoso, D; Roy, S; Rubin, BP; Schoffski, P; Taguchi, T; Trent, JA; Wang, WL, 2010) |
| "The high risk of recurrence in resected gastrointestinal stromal tumor (GIST) highlights the need for effective adjuvant treatment." | ( Cooper, K; Essat, M, 2011) |
| "The stomach is the most common site of gastrointestinal stromal tumors (GISTs), but the surgical outcomes of gastric GISTs in the era of targeted drug therapy are unclear." | ( Hao, XS; Huang, H; Li, H; Liang, H; Ren, XB; Zhan, ZL, 2012) |
| "We report a case of a residual stomach gastrointestinal stromal tumor (GIST) successfully treated with resection." | ( Ishii, Y; Kikuchi, D; Saitou, M; Takenoshita, S; Yamada, M, 2011) |
| "To analyze the impact of location of gastrointestinal stromal tumor(GIST) on the survival, and the influence of surgical treatment and imatinib therapy on survival." | ( Liu, LC; Xu, WT, 2012) |
| "The treatment of gastrointestinal stromal tumors (GISTs) with tyrosine kinase inhibitors (TKIs), such as imatinib and sunitinib, has produced improved outcomes and survival." | ( Koshenkov, VP; Rodgers, SE, 2012) |
| "Standard treatment for metastatic gastrointestinal stromal tumors (GISTs) is systemic therapy with imatinib." | ( Bonenkamp, JJ; de Wilt, JH; Gelderblom, H; Hartgrink, HH; Sleijfer, S; Tielen, R; van Coevorden, F; van der Graaf, WT; Verhoef, C, 2012) |
| "Patients with advanced gastrointestinal stromal tumors treated with frontline imatinib were analyzed." | ( Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, JH; Kim, SH; Kim, TY; Kim, WH; Koh, Y; Lee, HE; Lee, SH; Oh, DY, 2012) |
| "A 61-year-old woman with metastatic gastrointestinal stromal tumor (GIST) presented with NS and hypertension following therapy with sunitinib 400 mg/day." | ( Benekli, M; Buyukberber, S; Cetin, B; Guz, G; Inal, S; Memis, L; Ozturk, SC; Turan, N, 2012) |
| "Rectal gastrointestinal stromal tumors (GISTs) are uncommon, and the role of local excision versus a more extensive resection after the advent of effective targeted chemotherapy with imatinib is not known." | ( Centonze, D; Cinardi, N; Franco, S; Giannone, G; Pulvirenti D'Urso, A; Pulvirenti, E, 2013) |
| "Advanced gastrointestinal stromal tumors (GIST), a KIT oncogene-driven tumor, on imatinib mesylate (IM) treatment may develop secondary KIT mutations to confer IM-resistant phenotype." | ( Chen, LT; Chen, TS; Chiang, NJ; Hsueh, YS; Ko, CH; Li, CF; Lin, CL; Shan, YS; Shih, NY; Wang, LM; Yen, CC, 2013) |
| "Extragastrointestinal stromal tumors (eGISTs) of the mesoileum are extremely rare and are usually treated with surgery combined with imatinib therapy." | ( Kang, Y; Li, H; Li, J; Li, X; Wei, Q, 2013) |
| "Historically, patients with inoperable gastrointestinal stromal tumors (GISTs) had a very poor prognosis because of the highly resistant nature of these tumors to conventional chemotherapy." | ( Bae, S; Desai, J, 2014) |
| "Imatinib has changed the treatment of gastrointestinal stromal tumors (GISTs)." | ( Cats, A; Kol, S; Stiekema, J; van Coevorden, F; van Sandick, JW; Yazdi, AT, 2015) |
| "Most gastrointestinal stromal tumors (GIST) are caused by oncogenic KIT or platelet-derived growth factor receptor activation, and the small molecule kinase inhibitor imatinib mesylate is an effective first-line therapy for metastatic or unresectable GIST." | ( Boichuk, S; Brown, MF; Cuevas, R; Debiec-Rychter, M; Duensing, A; Korzeniewski, N; Kuan, SF; Lee, DJ; Makielski, KR; Mehalek, KR; Parry, JA; Schöffski, P; Seneviratne, DS; Taguchi, T; Wozniak, A; Zewe, J, 2014) |
| "One patient with gastrointestinal stromal tumor (GIST) who had progressive disease on imatinib had a partial response and remained on treatment for 10 months." | ( Ayrton, J; Dezube, BJ; Kwak, E; Lyons, J; Mahadevan, D; Shapiro, GI; Yule, M, 2015) |
| "To estimate the economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who received imatinib adjuvant therapy." | ( Gauthier, G; Guerin, A; Keir, CH; Sasane, M; Wu, EQ; Zhdavana, M, 2015) |
| "We report a case of gastrointestinal stromal tumor (GIST) locally resected after long-term chemotherapy with imatinib mesylate." | ( Cho, A; Denda, T; Ikeda, A; Kainuma, O; Muto, Y; Nabeya, Y; Nagata, M; Souda, H; Takano, E; Takiguchi, N; Tonooka, T; Yamamoto, H; Yanagibashi, H, 2014) |
| "He was diagnosed with unresectable gastrointestinal stromal tumor (GIST) and began imatinib treatment." | ( Doki, Y; Hara, H; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M, 2014) |
| "We report a case of a large gastric gastrointestinal stromal tumor (GIST), which became resectable and achieved pathological complete response after neoadjuvant chemotherapy with imatinib mesylate." | ( Fukuoka, E; Iwatani, Y; Kuroda, D; Mii, Y; Murata, K; Oka, S; Otsubo, D; Sawa, H, 2014) |
| "Diagnosis and staging of duodenal gastrointestinal stromal tumors (GISTs) by noninvasive imaging is critical for effective treatment, but the imaging features of duodenal GISTs remain largely undefined because of their rarity." | ( Cai, PQ; Fan, Y; Luo, ZP; Lv, XF; Mitteer, RA; Tian, L; Wu, YP, 2015) |
| "The treatment of gastrointestinal stromal tumor (GIST) has become sophisticated with the availability of three approved agents in many countries and 15 years of experience with primary and metastatic disease." | ( Blay, JY; Demetri, GD; Fletcher, JA; Joensuu, H; Maki, RG; Martín-Broto, J; Nishida, T; Reichardt, P; Schöffski, P; Trent, JC, 2015) |
| "Patients with advanced gastrointestinal stromal tumors (GIST) are currently recommended for treatment with tyrosine kinase inhibitors (TKI) in a life-long sequence." | ( Bruland, ØS; Hompland, I, 2015) |
| "The management of gastrointestinal stromal tumors (GIST) evolved due to effective molecularly targeted therapy with imatinib and sunitinib which are used first- and second-line, respectively." | ( Rutkowski, P; Stępniak, J, 2016) |
| "The first 15 years of management of gastrointestinal stromal tumor (GIST) have led to 3 lines of therapy for metastatic disease: imatinib, sunitinib, and regorafenib." | ( Maki, RG; Martínez-Marín, V, 2016) |
| "Most metastatic gastrointestinal stromal tumors (GISTs) develop resistance to the first-line imatinib treatment." | ( Aime, S; Cabodi, S; Consolino, L; Dastrù, W; Giovenzana, GB; Longo, DL; Sciortino, M, 2017) |
| "Anorectal gastrointestinal stromal tumors (GISTs) are exceedingly rare, and management remains controversial in regard to local resection (LR) and preoperative chemotherapy." | ( Glasgow, SC; Hawkins, AT; Hunt, SR; Krishnamurty, DM; Mutch, MG; Silviera, ML; Wells, KO; Wise, PE, 2017) |
| "The therapy for gastrointestinal stromal tumors (GIST) has changed significantly since the use of imatinib mesylate (IM)." | ( Cao, LL; Chen, QF; Chen, QY; Huang, CM; Li, P; Lin, JX; Lin, M; Lu, J; Tu, RH; Wang, JB; Xie, JW; Zheng, CH, 2017) |
| "We report a case of a huge gastric gastrointestinal stromal tumor(GIST)that was safely resected followingpreoperative imatinib therapy." | ( Abe, T; Aoki, T; Imoto, H; Ishioka, C; Karasawa, H; Motoi, F; Musha, H; Nagao, M; Naitoh, T; Ohnuma, S; Sato, Y; Takahashi, M; Tanaka, N; Unno, M; Watanabe, K, 2016) |
| "The fact that most gastrointestinal stromal tumors (GISTs) acquire resistance to imatinib (IM)-based targeted therapy remains the main driving force to identify novel molecular targets that are capable to increase GISTs sensitivity to the current therapeutic regimens." | ( Boichuk, S; Dunaev, P; Galembikova, A; Gusev, O; Khaiboullina, S; Shagimardanova, E; Valeeva, E, 2017) |
| "The acquired resistance of gastrointestinal stromal tumors (GISTs) to the targeted-based therapy remains the driving force to identify the novel approaches that are capable of increasing the sensitivity of GISTs to the current therapeutic regimens." | ( Boichuk, S; Dunaev, P; Galembikova, A; Mustafin, I; Valeeva, E, 2018) |
| "While the treatment of gastrointestinal stromal tumors (GISTs) has been revolutionized by the application of targeted tyrosine kinase inhibitors capable of inhibiting KIT-driven proliferation, diverse mutations to this kinase drive resistance to established therapies." | ( Anjum, R; Barry, E; Bhavsar, D; Boyd, S; Brown, C; Campbell, A; Goldberg, K; Grondine, M; Guichard, S; Hardy, CJ; Hunt, T; Jones, RDO; Kettle, JG; Li, X; Moleva, O; Ogg, D; Overman, RC; Packer, MJ; Pearson, S; Schimpl, M; Shao, W; Smith, A; Smith, JM; Stead, D; Stokes, S; Tucker, M; Ye, Y, 2018) |
| "We report a case of gastrointestinal stromal tumor(GIST)with long-term survival treated by multidisciplinary therapy, including surgery and imatinib to prevent repeated recurrence." | ( Deguchi, S; Hirakawa, K; Hori, T; Iimori, N; Ishikawa, T; Masuda, G; Nakao, S; Nakata, B; Ohira, M; Sakimura, C; Tendo, M, 2018) |
| "The treatment of gastrointestinal stromal tumors (GIST) has dramatically improved since the introduction of small molecule KIT proto-oncogene receptor tyrosine kinase inhibitors." | ( Bauer, S; Falkenhorst, J; Hamacher, R; Treckmann, J, 2019) |
| "As the first-line treatment of gastrointestinal stromal tumor (GIST), the pharmacokinetic and pharmacodynamic of imatinib (IM) were characterized by marked interindividual variability." | ( Cai, W; Chen, H; Hou, Y; Liu, J; Ma, G; Zhou, Y, 2019) |
| "Nearly all patients with advanced gastrointestinal stromal tumor (GIST) develop resistance to imatinib, and subsequent treatments have limited efficacy." | ( Adamson, T; Antonescu, CR; Chi, P; Condy, M; D'Angelo, SP; Dickson, MA; Gounder, M; Hwang, S; Kelly, C; Keohan, ML; Mcfadyen, CR; Movva, S; Qin, LX; Rosenbaum, E; Singer, S; Tap, WD, 2019) |
| "The targeting and therapy of gastrointestinal stromal tumors (GIST) using nonsticky and renal clearable theranostic nanoparticles (a." | ( Baek, Y; Bao, K; Choi, HS; Coll, JL; Hu, S; I, H; Jo, MJ; Kang, H; Nomura, S; Park, GK; Rubin, BP; Stiles, WR, 2020) |
| "The optimal treatment for gastrointestinal stromal tumor (GIST) of the rectum is controversial due to the extremely low incidence of the disease." | ( Fang, Y; Fu, M; Gao, XD; Hou, YY; Qin, J; Qin, XY; Shen, KT; Shu, P; Sun, XF; Sun, YH; Xue, AW, 2020) |
| "The majority of gastrointestinal stromal tumors (GISTs) are driven by oncogenic KIT signaling and can therefore be effectively treated with the tyrosine kinase inhibitor (TKI) imatinib mesylate." | ( Agha, A; Ali, AA; Debiec-Rychter, M; Dhillon, HS; Duensing, A; Gebreyohannes, YK; Lee, DM; Makielski, KR; Mehalek, KR; Patil, SS; Rausch, JL; Schöffski, P; Tolstov, Y; Wellens, J; Wozniak, A, 2020) |
| "The diagnosis and treatment of gastrointestinal stromal tumor (GIST) is getting more and more standardized." | ( Wang, M; Zhao, G; Zhao, WY, 2020) |
| "Although high-risk gastrointestinal stromal tumors (GISTs) frequently recur, even after a complete resection and imatinib therapy, local recurrence at the suture line after complete resection is rare." | ( Kim, BJ; Kim, HJ; Kim, HS; Kim, JG; Park, JM; Park, JY, 2020) |
| "Most gastrointestinal stromal tumors (GIST) driven by KIT or platelet-derived growth factor receptor A (PDGFRA) mutations develop resistance to available tyrosine kinase inhibitor (TKI) treatments." | ( Bauer, S; Cassier, PA; Chawla, SP; Eskens, F; George, S; Gordon, M; Heinrich, MC; Jones, RL; Kang, YK; Meiri, E; Mir, O; Patel, S; Roche, M; Rutkowski, P; Schöffski, P; Serrano, C; Tap, WD; Trent, J; von Mehren, M; Zhou, T, 2021) |
| "Duodenal gastrointestinal stromal tumors (dGISTs) are rare, and a lack of consensus exists regarding their treatment, particularly for recurrent disease." | ( Ikeda, M; Inoue, M; Kajikawa, R; Kajiwara, R; Miyamoto, K; Ohmori, I; Sadamoto, S; Sawada, H; Shishida, M; Takahashi, T; Toyota, K; Watanabe, A, 2021) |
| "A 35-mm rectal gastrointestinal stromal tumor(GIST)was treated by laparoscopic ultra-low rectal resection and transanal anastomosis following trans-anal rectal dissection by perineal manipulation." | ( Funahashi, K; Ikeda, Y; Kagami, S; Kaneko, T; Kurihara, A; Mitsuda, A; Miura, Y; Nagashima, Y; Tochigi, N; Ushigome, M; Yoshino, S; Yoshino, Y, 2021) |
| "Surgery is the cornerstone of gastrointestinal stromal tumor (GIST) treatment, and adjuvant therapy with imatinib has improved survival for high-risk tumors." | ( Åhlen, J; Bränström, R; Haglund de Flon, F; Jalmsell, L; Karlsson, F; Linder-Stragliotto, C; Papakonstantinou, A; Renberg, S; Zhang, Y, 2022) |
| "Rectal gastrointestinal stromal tumors are rare and optimal treatment is yet to be defined." | ( Amaadour, L; Arifi, S; Benbrahim, Z; Berrad, S; Mellas, N; Oualla, K, 2022) |
| "Patients with rectal gastrointestinal stromal tumors (GISTs) who achieve a complete response (CR) with imatinib therapy have rarely been reported in the literature." | ( Chen, W; Cheng, X; Wu, T, 2022) |
| "KIT is frequently mutated in gastrointestinal stromal tumors (GISTs), and the treatment of GISTs largely relies on targeting KIT currently." | ( Bai, R; Cao, X; Fan, Z; Li, S; Liang, N; Liu, A; Sun, J; Tian, J; Wang, M; Xiao, K; Yu, Y; Zhang, L; Zhang, S; Zhao, H; Zhao, S; Zhou, L, 2023) |
| "A patient with gastrointestinal stromal tumor was referred to our clinical pharmacology service due to tumor progression while on imatinib therapy." | ( Buonadonna, A; Canil, G; Cecchin, E; Dalle Fratte, C; Gagno, S; Guardascione, M; Orleni, M; Posocco, B; Roncato, R; Toffoli, G; Zanchetta, M, 2023) |